A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Abroad (travel likely)RecruitingPHASE1

Conditions

Relapsed/Refractory Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peter MacCallum Cancer Center, Parkville, Victoria, Australia

Study leads

Clinical Trials
Study Director
Hoffmann-La Roche

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Guangzhou, China · Tianjin, China

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Coral Gables, United States · Deerfield Beach, United States

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma · Relapse Multiple Myeloma · Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Boston, United States · Boston, United States

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Hematologic Malignancy · Large B-cell Lymphoma · Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE1

Los Angeles, United States